新型血管网络的发展是肿瘤生长和进展的基本要求。在过去的十年中，人们对血管生成的生物标志物和潜在分子途径进行了深入研究，以破坏肿瘤血管生成的启动和进展。然而，由于毒副作用、获得性耐药性和经过验证的生物标志物的缺乏，抗血管生成剂的临床应用受到限制。这篇综述讨论了树枝状纳米载体的开发，这可能是一个有前途的领域，可以探索消除当前相关挑战基于血管生成的癌症治疗。具有微妙读数和更好地理解分子机制的新型药物递送方法表明，树枝状大分子具有先天的抗血管生成活性，并且抗血管生成剂或基因沉默RNA的掺入可以产生协同的抗血管生成和抗癌作用，同时减少副作用树枝状大分子介导的血管生成生物标志物靶向有效地导致了血管正常化，并且树枝状大分子与抗血管生成剂或siRNA或两者的合理连接可能是消除当前基于血管生成的癌症治疗挑战的潜在领域。然而，与树枝状大分子介导的血管生成生物标志物靶向相关的缺点，例如这些生物标志物在正常细胞上的稳定性差或表达量小，限制了其在市场规模上的应用。

Development of novel vascular networks is a fundamental requirement for tumor growth and progression. In the last decade, biomarkers and underlying molecular pathways of angiogenesis have been intensely investigated to disrupt the initiation and progression of tumor angiogenesis. However, the clinical applications of anti-angiogenic agents are constrained due to toxic side effects, acquired drug resistance and unavailability of validated biomarkers.This review discusses the development of dendrimeric nanocarriers that could be a promising domain to explore for the eradication of current challenges associated with angiogenesis-based cancer therapy. Novel drug-delivery approaches with subtle readouts and better understanding of molecular mechanisms have revealed that dendrimers comprise innate anti-angiogenic activity and incorporation of anti-angiogenic agents or gene-silencing RNA could lead to synergistic anti-angiogenic and anticancer effects with reduced side effects.Dendrimer-mediated targeting of angiogenic biomarkers have efficiently led to the vascular normalization, and rational linking of dendrimers with anti-angiogenic agent or siRNA or both might be a potential area to eradicate the current challenges of angiogenesis-based cancer therapy. However, drawbacks associated with the dendrimers-mediated targeting of angiogenic biomarkers, such as poor stability or small expression of these biomarkers on the normal cells, limits it application at market scale.